Evidence map›Paper›PMID 39126091›Full record

ReviewInternational journal of molecular sciences2024

Innate Immune Cells in Melanoma: Implications for Immunotherapy.

Marialuisa Trocchia, Annagioia Ventrici, Luca Modestino, Leonardo Cristinziano, Anne Lise Ferrara, Francesco Palestra, Stefania Loffredo, Mariaelena Capone, Gabriele Madonna, Marilena Romanelli and 2 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Interactions Between Tryptase-Positive Mast Cells and Melanin-AInternational journal of molecular sciences · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Metabolism of tumor infiltrating T cells.Frontiers in immunology · 2025
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marialuisa TrocchiaDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.
Annagioia VentriciDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.
Luca ModestinoDepartment of Internal Medicine and Clinical Immunology, University Hospital of Naples Federico II, 80138 Naples, Italy.
Leonardo CristinzianoCenter for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0002-7835-2212
Anne Lise FerraraDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0003-1839-8873
Francesco PalestraDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0001-6145-7475
Stefania LoffredoDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0002-5871-1898
Mariaelena CaponeMelanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80138 Naples, Italy.ORCID 0000-0002-1352-2532
Gabriele MadonnaMelanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80138 Naples, Italy.ORCID 0000-0001-9395-3190
Marilena RomanelliMelanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80138 Naples, Italy.ORCID 0009-0004-4822-4772
Paolo Antonio AsciertoMelanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80138 Naples, Italy.ORCID 0000-0002-8322-475X
Maria Rosaria GaldieroDepartment of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0002-8086-9130

Funding

Italian Association for Cancer Research 25123Ministero della Salute PNRR-MAD-2022-12376769
6 · The paper itself

Abstract

The innate immune system, composed of neutrophils, basophils, eosinophils, myeloid-derived suppressor cells (MDSCs), macrophages, dendritic cells (DCs), mast cells (MCs), and innate lymphoid cells (ILCs), is the first line of defense. Growing evidence demonstrates the crucial role of innate immunity in tumor initiation and progression. Several studies support the idea that innate immunity, through the release of pro- and/or anti-inflammatory cytokines and tumor growth factors, plays a significant role in the pathogenesis, progression, and prognosis of cutaneous malignant melanoma (MM). Cutaneous melanoma is the most common skin cancer, with an incidence that rapidly increased in recent decades. Melanoma is a highly immunogenic tumor, due to its high mutational burden. The metastatic form retains a high mortality. The advent of immunotherapy revolutionized the therapeutic approach to this tumor and significantly ameliorated the patients' clinical outcome. In this review, we will recapitulate the multiple roles of innate immune cells in melanoma and the related implications for immunotherapy.

Indexed as

Immunity, InnateImmunotherapyMelanomaAnimalsCutaneous Malignant MelanomaDendritic CellsHumansMast CellsSkin Neoplasmsdendritic cellsimmune checkpoint inhibitorsimmunotherapymacrophagesmelanomamonocytesneutrophilsneutrophils extracellular trapstumor microenvironment

Identifiers

PMID39126091
PMCPMC11313504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.